| Louisville Geriatric Associates | |
|
443 Spring St Ste 200 Jeffersonville IN 47130-4494 | |
| (812) 288-8360 | |
| (812) 288-8375 |
| Full Name | Louisville Geriatric Associates |
|---|---|
| Speciality | Internal Medicine |
| Location | 443 Spring St Ste 200, Jeffersonville, Indiana |
| Authorized Official Name and Position | Muhammad I Masroor (OWNER) |
| Authorized Official Contact | 8122888360 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Louisville Geriatric Associates 443 Spring St Ste 200 Jeffersonville IN 47130-4494 Ph: (812) 288-8360 | Louisville Geriatric Associates 443 Spring St Ste 200 Jeffersonville IN 47130-4494 Ph: (812) 288-8360 |
| NPI Number | 1871508614 |
|---|---|
| Provider Enumeration Date | 07/30/2006 |
| Last Update Date | 08/20/2020 |
| Medicare PECOS PAC ID | 1557380086 |
|---|---|
| Medicare Enrollment ID | O20051115000042 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871508614 | NPI | - | NPPES |
| 65945818 | Medicaid | KY | |
| 78905429 | Medicaid | KY |
| Provider Name | Muhammad I Masroor |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1043216971 PECOS PAC ID: 5092734525 Enrollment ID: I20051116000149 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Virginia Lee Nisbet |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053441444 PECOS PAC ID: 7416967575 Enrollment ID: I20101203001136 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Van T Tuong |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1972660678 PECOS PAC ID: 4284818618 Enrollment ID: I20110411000121 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Tina M Woodrome-nethery |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962759274 PECOS PAC ID: 4183872021 Enrollment ID: I20120918000366 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Amy N Ledford |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790126696 PECOS PAC ID: 5294977047 Enrollment ID: I20130807001065 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Brooke A Miller |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598105660 PECOS PAC ID: 1456595636 Enrollment ID: I20130910000934 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Stacy M Garcia |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588023675 PECOS PAC ID: 7618272733 Enrollment ID: I20160301001814 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Brittany D Clunie |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427546373 PECOS PAC ID: 9436413309 Enrollment ID: I20181204001179 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Lindsay R Jones |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336615384 PECOS PAC ID: 8325392319 Enrollment ID: I20190201001700 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Amanda J Wade |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922561653 PECOS PAC ID: 8022350966 Enrollment ID: I20190425001122 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Michelle L Vissing |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740849637 PECOS PAC ID: 0941537906 Enrollment ID: I20190827000599 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Christian E Reid |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366917544 PECOS PAC ID: 2264761915 Enrollment ID: I20190916003576 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Vanessa H Higgins |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235594383 PECOS PAC ID: 4880983527 Enrollment ID: I20200623001687 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Jessica Raquel Perez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902575715 PECOS PAC ID: 6305236803 Enrollment ID: I20211123002513 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Joanna L Gullion |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1669142477 PECOS PAC ID: 1153711874 Enrollment ID: I20211230000652 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Trista Bodenstadt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205597515 PECOS PAC ID: 4284026840 Enrollment ID: I20221006002845 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Megan Horvath |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073222030 PECOS PAC ID: 0648640383 Enrollment ID: I20230118002219 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
| Provider Name | Jose Bada |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1063595452 PECOS PAC ID: 5193791713 Enrollment ID: I20230316002623 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
Indiana University researchers have identified a mechanism involving the body's ability to resist fungal infection. The work could help advance research on cancer therapies that use the body's own immune system to fight disease.
Less-educated white women were increasingly more likely to die than their better-educated peers from the mid-1990s through the mid-2000s, according to a new study, which found that growing disparities in economic circumstances and health behaviors-particularly employment status and smoking habits-across education levels accounted for an important part of the widening mortality gap.
Initiative to promote the benefit of using Thermo Fisher Scientific's library prep kits with SPT Labtech's instruments to help reduce reagent and material requirements for high-throughput genome sequencing.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 4 days ago
Physician's Care Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1804 E 10th St, Jeffersonville, IN 47130 Phone: 812-288-2488 Fax: 812-288-6603 | |
Crossover Health Medical Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 434 Patrol Rd, Jeffersonville, IN 47130 Phone: 949-891-0328 | |
Jeffersonville Family Practice Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1035 Wall St, Suite 204, Jeffersonville, IN 47130 Phone: 812-288-8410 Fax: 812-288-8409 | |
Shaze Medical Group Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1035 Wall Street Ste 104-c1, Jeffersonville, IN 47130 Phone: 812-282-2218 Fax: 812-282-2252 | |
Viverant Integrative Clinic Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 335 Spring St Ste B, Jeffersonville, IN 47130 Phone: 812-255-1699 | |
New Life Family Resources Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1101 Spring St # 2, Jeffersonville, IN 47130 Phone: 812-288-1470 Fax: 812-288-2717 | |
Havens Medical Group Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 207 Sparks Avenue, Suite 200, Jeffersonville, IN 47130 Phone: 812-283-4441 Fax: 812-288-2605 |